RxDoctor Payments DataLook up a doctor →

Raj Mulpuri, MD

Pulmonary Disease · Surprise, AZNPI 1669460853

Payments from drug & device makers

$14,401in general payments, 2019–2025

Across 658 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$2K
  • Mylan Specialty L.p.$1K
  • Harmony Biosciences LLC$594
  • Insmed, Inc.$516
  • plus $6K from 47 others

What the payments were for

  • Food & beverage$14,05698%
  • Education$3452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,401 in reported general payments places this provider in the 75th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$381,487
Medicare patients
981
Services billed
4,654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,204$1,024,618
OfevNintedanib Esylate46$606,023
Spiriva RespimatTiotropium Bromide292$187,722
AdempasRiociguat11$154,964
Breo ElliptaFluticasone/Vilanterol168$83,525
Breztri AerosphereBudesonide/Glycopyr/Formoterol80$56,775
Pirfenidone11$53,790
Fluticasone-SalmeterolFluticasone Propion/Salmeterol244$49,456
SymbicortBudesonide/Formoterol Fumarate83$28,112
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$27,878
Advair HfaFluticasone Propion/Salmeterol34$20,855
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$18,660
EliquisApixaban18$15,183
Albuterol Sulfate HfaAlbuterol Sulfate573$14,438
Qvar RedihalerBeclomethasone Dipropionate52$14,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,930$1,142,4211,456 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,656$821,622364 claims
BayerAdempas$18$154,96411 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,169$84,887163 claims
PfizerEliquis$94$15,18318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →